Loading...
•
Sep 30, 2020
Sage Q3 2020 Earnings Report
Sage Therapeutics reported financial results for the third quarter ended September 30, 2020 and highlighted pipeline and business progress.
Key Takeaways
Sage Therapeutics reported $1.6 million in net revenue from sales of ZULRESSO in Q3 2020, compared to $1.5 million for the same period in 2019. The company's clinical programs across three franchises remain on track, with key milestones anticipated over the next 12 to 18 months.
Zuranolone Phase 3 pivotal trials in major depression and postpartum depression are progressing well; expect to initiate dosing in CORAL Study in 4Q 2020
Continued execution across brain health franchises highlighted during 2nd annual FutureCast event
First patient dosed in PARADIGM Study investigating SAGE-718 in patients with Parkinson’s disease cognitive dysfunction
Company anticipates a cash balance of at least $550 million at end of 2020, which the Company anticipates will support operations into 2022 based on current operating plans.
Forward Guidance
Sage anticipates a cash balance of at least $550 million at end of 2020, which the Company anticipates will support operations into 2022 based on current operating plans.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...